RT Journal Article
SR Electronic
T1 Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 383
OP 385
DO 10.3899/jrheum.131085
VO 41
IS 2
A1 Conaghan, Philip G.
A1 McQueen, Fiona M.
A1 Bird, Paul
A1 Peterfy, Charles
A1 Haavardsholm, Espen
A1 Gandjbakhch, Frédérique
A1 Eshed, Iris
A1 Haugen, Ida K.
A1 Lillegraven, Siri
A1 Døhn, Uffe Møller
A1 Ejbjerg, Bo
A1 Foltz, Violaine
A1 Coates, Laura
A1 Bøyesen, Pernille
A1 Hermann, Kay-Geert
A1 Freeston, Jane
A1 Lassere, Marissa
A1 O’Connor, Philip
A1 Emery, Paul
A1 Genant, Harry
A1 Østergaard, Mikkel
YR 2014
UL http://www.jrheum.org/content/41/2/383.abstract
AB Magnetic resonance imaging (MRI) provides an important biomarker across a range of rheumatological diseases. At the Outcome Measures in Rheumatology (OMERACT) 11 meeting, the MRI task force continued its work of developing and improving the use of MRI outcomes for use in clinical trials. The breadth of pathology in the Rheumatoid Arthritis MRI Score has been strengthened with further work on the development of a joint space narrowing score, and a series of exercises presented at OMERACT 11 demonstrated good reliability and construct validity for this assessment. Understanding the importance of residual inflammation after RA treatment remains a major focus of the group’s work. Analyses were presented on defining the level of synovitis (using MRI scores of a single hand) that would predict absence of erosion progression. The development of the OMERACT Hand Osteoarthritis MRI score has continued with substantial work presented on its iterative development, including pathology definition, scaling, and subsequent reliability of the score. Optimizing the role of MRI as a robust biomarker and surrogate outcome remains a priority for this group.